Crystalys Therapeutics
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
$130MSeries B
Role not disclosedNH
Novo Holdings
Activity from announced rounds
Activity in this selectionsymbolic-capital-f3f73206
- Rounds participated in
- 3
- Confirmed lead rounds
- — 3 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $313M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionTerremoto Biosciences
Develops highly targeted, small molecule medicines for cancer and rare diseases
$108MSeries C
Role not disclosedAdcendo
Adcendo develops antibody-drug conjugates that deliver cancer drugs to tumor-associated targets, with clinical programs in solid tumors and soft tissue sarcoma.
$75MSeries C
Role not disclosed